Ilham Akhsanu Ridlo does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...
Multi-year agreement supports research community of 2,500+ membersHOBOKEN, N.J., October 23, 2025 - Wiley (NYSE: WLY), a global leader in ...
Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer. Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback